{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T09:44:06Z","timestamp":1753868646283,"version":"3.41.2"},"reference-count":29,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T00:00:00Z","timestamp":1690502400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Human epidermal growth factor receptor 2 (HER2) overexpression is an independent prognostic factor of poor prognosis and a predictor of efficacy of anti\u2010HER2 therapy. A limited number of patients can receive standard second\u2010line therapy (DS\u20108201 or T\u2010DM1) for metastatic HER2\u2010positive in some parts of the world, including China, due to many factors, such as cost\u2013benefit ratios.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case<\/jats:title><jats:p>A 51\u2010year\u2010old premenopausal woman was diagnosed with HER2\u2010positive breast cancer. The pathological stage was ypT3N2M0 and stage IIIA. Trastuzumab targeted therapy combined with goserelin depot was started along with letrozole endocrine therapy. After eight courses of treatment, magnetic resonance imaging (MRI) examination revealed new multiple metastases in the liver, and progression disease (PD) was evaluated. Due to abnormal activation of the phosphatidylinositol 3\u2010kinase\/protein kinase B\/mammalian target of rapamycin (PI3K\/AKT\/mTOR) pathway in the patient, treatment was changed to the mammalian target of rapamycin (mTOR) inhibitor combined with the anti\u2010HER\u20102 agents inetetamab and paclitaxel, while partial response (PR) was evaluated after 6\u2009cycles of treatment. As the patient was hormone receptor (HR) positive, treatment was changed to the inetetamab + rapamycin + exemestane regimen. The lesion continued to shrink and PR was evaluated for 8\u2009cycles. The original regimen was continued, PR was evaluated after 12 courses of treatment. The abdominal MRI performed showed an increase in the volume of intrahepatic multiple metastatic tumor lesion. Efficacy was used to assess for PD and the progression\u2010free survival (PFS) was 317\u2009days.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A phosphatidylinositol\u20104, 5\u2010bisphosphate 3\u2010kinase catalytic subunit alpha (PIK3CA) mutation in trastuzumab\u2010treated metastatic HER2\u2010positive breast cancer female had a long PFS by treating with the mammalian target of rapamycin inhibitor in combination with the anti\u2010HER\u20102 agent inetetamab.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.1864","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T07:18:43Z","timestamp":1690528723000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Inetetamab in combination with rapamycin and chemotherapy for trastuzumab\u2010treated metastatic <scp>human epidermal growth factor receptor 2<\/scp>\u2010positive breast cancer with abnormal activation of <scp>PI3K\/Akt\/mTOR<\/scp> pathway"],"prefix":"10.1002","volume":"6","author":[{"given":"Aijuan","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Oncology Anqing Municipal Hospital  Anqing Anhui China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5884-2265","authenticated-orcid":false,"given":"Chenghui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology Anqing Municipal Hospital  Anqing Anhui China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi'an","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology Anqing Municipal Hospital  Anqing Anhui China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Oncology Anqing Municipal Hospital  Anqing Anhui China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,7,28]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2019.08.012"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2020.02.016"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14205115"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1006429"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2020.01.009"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29040208"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.SABCS12-S5-5"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1090326"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15071987"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2656"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14123003"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw197"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.5384"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102064"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2000648117"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1159\/000512283"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.628690"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-04328-y"},{"issue":"2","key":"e_1_2_12_21_1","first-page":"179","article-title":"Targeted lapatinib anti\u2010HER2\/ErbB2 therapy resistance in breast cancer: opportunities to overcome a difficult problem","volume":"3","author":"Wahdan\u2010Alaswad R","year":"2020","journal-title":"Cancer Drug Resist"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22010173"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.21037\/tbcr-21-42"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0060-1"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02179"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.04.004"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70138-X"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1515\/biol-2022-0535"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2017.03.004"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.937"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.1864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,6]],"date-time":"2023-09-06T04:33:33Z","timestamp":1693974813000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.1864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,28]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1002\/cnr2.1864"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.1864","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2023,7,28]]},"assertion":[{"value":"2023-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1864"}}